BioLineRx (BLRX) Reports In-Line Q1 EPS

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $0 versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Driven Brands (DRVN) Tops Q4 EPS by 2c, Misses on Revenue; Offers FY26 Guidance
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance